Academic Journal
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasone.
| Τίτλος: | Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT |
|---|---|
| Συγγραφείς: | Aoyama T; Department of Pharmacy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. takeshi.aoyama@jfcr.or.jp., Iihara H; Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu, 501-1194, Gifu, Japan., Abe M; Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Shizuoka, Japan., Wada M; Department of Psycho-Oncology, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Osaka, Japan., Iino K; School of Nursing, National College of Nursing, 1-2-1, Umezono, Kiyose, Tokyo, 204-8575, Japan., Akechi T; Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho- cho, Mizuho-ku, Nagoya, 467-8601, Japan., Imamura CK; Advanced Cancer Translational Research Institute, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan., Okuyama A; Graduate School of Nursing Science, St. Luke's International University, 10-1 Akashi-cho, Chuo-ku, Tokyo, 104-0044, Japan., Ozawa K; Division of Survivorship, Institute for Cancer Control, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan., Kim YI; Division of Medical Oncology, Yodogawa Christian Hospital, 1-7-50 Kunijima, Higasiyodogawa-ku, Osaka, 533-0024, Osaka, Japan., Sasaki H; Division of Medical Oncology, Hematology and Infectious Disease, Fukuoka University Hospital, 7-45-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Fukuoka, Japan., Satomi E; Department of Palliative Medicine, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan., Takeda M; Department of Cancer Genomics and Medical Oncology, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8521, Nara, Japan., Tanaka R; Department of Pediatric Hematology/Oncology, International Medical Center, Saitama Medical University, 1398-1 Yamane, Hidaka, 350-1298, Saitama, Japan., Nakajima TE; Department of Early Clinical Development, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan., Nakamura N; Department of Radiation Oncology, St. Marianna University, 2-16-1 Sugao, Miyamae, Kawasaki, 216-8511, Kanagawa, Japan., Nishimura J; Department of Gastroenterological Surgery, Osaka International Cancer Institute, 3-1-69, Otemae, Chuo-ku, Osaka, 541-8567, Osaka, Japan., Noda M; Non-profit Organization Sasaeau-kai 'Alpha', 518-7 Kawado-cho, Chuo-ku, Chiba, 260-0802, Chiba, Japan., Hayashi K; Department of Clinical Oncology and Hematology, The Jikei University School of Medicine, 3-25-8 Nishi-shinnbashi, Minato-ku, Tokyo, 105-8461, Japan., Higashi T; Department of Public Health and Health Policy, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan., Boku N; Department of Oncology and General Medicine, Institute of Medical Science, IMSUT Hospital, University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan., Matsumoto K; Division of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi, 673-0021, Hyogo, Japan., Matsumoto Y; Non-profit Organization Ehime Cancer Support 'Orange-no-kai', 3-8- 24 Furukawaminami, Matsuyama, 790-0943, Ehime, Japan., Okita K; Department of Surgery, Otaru Ekisaikai Hospital, 1-4-1, Inaho, Otaru, 047-0032, Hokkaido, Japan., Yamamoto N; Internal Medicine III, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Wakayama, Japan., Aogi K; Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, 160 Kou, Minamiumemoto-machi, Matsuyama, 791-0280, Ehime, Japan. |
| Πηγή: | International journal of clinical oncology [Int J Clin Oncol] 2026 Sep; Vol. 31 (9), pp. 1735-1741. Date of Electronic Publication: 2026 Jul 21. |
| Τύπος έκδοσης: | Journal Article; Systematic Review; Comparative Study |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 1998- : Tokyo : Springer-Verlag Tokyo Original Publication: Tokyo : Published for the Japan Society of Clinical Oncology by Churchill Livingstone, c1996- |
| Ιατρικοί όροι (MeSH): | Dexamethasone*/therapeutic use , Serotonin 5-HT3 Receptor Antagonists*/therapeutic use , Antiemetics*/therapeutic use , Vomiting*/chemically induced , Vomiting*/drug therapy , Vomiting*/prevention & control , Nausea*/chemically induced , Nausea*/drug therapy , Antineoplastic Agents*/adverse effects , Neoplasms*/drug therapy, Humans ; Quality of Life |
| Περίληψη: | Background: Chemotherapy-induced nausea and vomiting (CINV) significantly impact quality of life of patients with cancer. Although antiemetic guidelines exist for low-emetic chemotherapy (LEC), recommendations vary across international guidelines and direct evidence comparing 5-HT3 receptor antagonists (5-HT3 RAs) with dexamethasone monotherapy is lacking. Methods: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for randomized controlled trials, nonrandomized comparative studies, and observational studies directly comparing 5-HT Results: A systematic search identified 427 articles (87 from PubMed, 337 from the Cochrane Library, and three from Ichushi-Web), with three additional records identified through other sources. After the first screening of 430 articles, 425 records were excluded, and five records were used for full-text assessment. Following the second screening, five full-text articles were excluded for not meeting the inclusion criteria. Conclusions: This systematic review identified no direct comparative evidence. Future efforts to strengthen the evidence base should include not only prospective comparative trials where feasible but also observational studies, real-world data analyses, and other complementary approaches that better reflect routine clinical practice. (© 2026. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.) |
| Competing Interests: | Declarations. Conflict of interest: Hirotoshi Iihara received honoraria from Taiho Pharmaceutical Co., Ltd. Tatsuo Akechi has received lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Kowa Co., Ltd., Lundbeck Japan K.K., MSD K.K., Meiji Seika Pharma Co., Ltd., Merck Biopharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Sumitomo Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Tsumura & Co., UCB Japan Co., Ltd., and Viatris Inc.; a grant from Shionogi & Co., Ltd.; and royalties from Igaku-Shoin, outside the submitted work. TA also serves as the representative director of the General Incorporated Association NCU CRESS and receives compensation as an advisor to Snom Inc. TA has pending patents (2020-135195, 2024-516288, and 2025-128748) and a granted patent (7313617), all assigned to his institution. Chiyo K. Imamura received research funding from Otsuka Pharmaceutical Co., Ltd. Eriko Satomi received honoraria from Shionogi & Co., Ltd. Masayuki Takeda received honoraria from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., Bristol Myers Squibb K.K., Janssen Pharmaceutical K.K., and Ono Pharmaceutical Co., Ltd. Takako Eguchi Nakajima received research funding from IQVIA Solutions Japan K.K., Thermo Fisher Scientific, Immunohelix, Ono Pharmaceutical Co., Ltd., BTB Therapeutics, Toregem BioPharma Co., Ltd., Advanced Accelerator Applications International, and Imel Therapeutics. Narikazu Boku received honoraria from Astellas Pharma Inc., Bristol Myers Squibb K.K., Taiho Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K., and research funding from Pfizer Inc. Koji Matsumoto received honoraria from MSD K.K., Kyowa Kirin Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Gilead Sciences, Inc., Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd.; and research funding from Daiichi Sankyo Co., Ltd., MSD K.K., Gilead Sciences, Inc., and Eli Lilly Japan K.K. Nobuyuki Yamamoto received honoraria from MSD K.K., AstraZeneca K.K., AbbVie GK, Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., JAPAC, GlaxoSmithKline K.K., Daiichi Sankyo Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Tsumura & Co., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novocure Ltd., Pfizer Japan Inc., Merck Biopharma Co., Ltd., Janssen Pharmaceutical K.K., and Regeneron: Science of Medicine; research funding from MSD K.K., AstraZeneca K.K., AbbVie GK, Amgen K.K.,GlaxoSmithKline K.K., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Novocure Ltd., Parexel International Inc., Bristol Myers Squibb K.K., Medpace Japan K.K., Mebix, Inc., and Janssen Pharmaceutical K.K.; and scholarship donations from Nippon Kayaku Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Kyowa Kirin Co., Ltd. The other authors declare no conflicts of interest. Ethics approval: Not applicable (systematic review of published literature). |
| References: | Cancer Med. 2025 Aug;14(15):e71079. (PMID: 40741776) Iran J Pharm Res. 2012 Fall;11(4):1059-64. (PMID: 24250537) BMJ. 2021 Mar 29;372:n71. (PMID: 33782057) Ann Oncol. 2010 May;21 Suppl 5:v232-43. (PMID: 20555089) Mayo Clin Proc. 2006 Oct;81(10):1361-7. (PMID: 17036562) Ann Oncol. 2006 Sep;17(9):1441-9. (PMID: 16766588) J Clin Oncol. 2020 Aug 20;38(24):2782-2797. (PMID: 32658626) Ann Oncol. 1996 Feb;7(2):189-95. (PMID: 8777177) Anticancer Res. 2021 Jul;41(7):3643-3648. (PMID: 34230162) N Engl J Med. 2016 Apr 7;374(14):1356-67. (PMID: 27050207) J Clin Oncol. 1998 Apr;16(4):1568-73. (PMID: 9552067) Clin Rev Allergy Immunol. 2015 Oct;49(2):177-91. (PMID: 24740483) J Clin Oncol. 1997 Jan;15(1):103-9. (PMID: 8996130) Br J Cancer. 2006 Apr 10;94(7):1011-5. (PMID: 16552437) |
| Contributed Indexing: | Keywords: 5-HT3; Chemotherapy-induced nausea and vomiting; Dexamethasone; Low emetogenic chemotherapy; Systematic review; receptor antagonists |
| Substance Nomenclature: | 7S5I7G3JQL (Dexamethasone) 0 (Serotonin 5-HT3 Receptor Antagonists) 0 (Antiemetics) 0 (Antineoplastic Agents) |
| Entry Date(s): | Date Created: 20260721 Date Completed: 20260825 Latest Revision: 20261008 |
| Update Code: | 20261008 |
| DOI: | 10.1007/s10147-026-03120-0 |
| PMID: | 42479257 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1437-7772 |
|---|---|
| DOI: | 10.1007/s10147-026-03120-0 |